Jak se v medicíně připravujeme na svět 4.0?

prof. MUDr. Vladimír Mihál CSc.,

Psychiatr. praxi 2018; 19(2): 43  

Neuropsychiatric symptoms in Parkinson’s disease in older age

MUDr. Vanda Franková, MUDr. Ivana Horská

Psychiatr. praxi 2018; 19(2): 48-51 | DOI: 10.36290/psy.2018.012  

Neuropsychiatric symptoms are very common in Parkinson’s disease, especially in its later stage. They are often under-recognizedand poorly managed. Early intervention may prevent progression of symptoms and development of life-threatening behaviour.Clinicians are advised to routinely screen for psychiatric symptoms in the office and modify Parkinson’s disease treatment accordinglyor consider the addition of psychopharmacotherapy: rivastigmine in dementia and psychosis, SSRI or other antidepressivemedication in anxiety and depression, an atypical antipsychotic (quetiapine, clozapine) in low doses in psychosis or aggressivebehaviour if necessary....

Novel treatment possibilities in depression and schizophrenia

prof. MUDr. Eva Češková, CSc.

Psychiatr. praxi 2018; 19(2): 53-56 | DOI: 10.36290/psy.2018.013  

In medicine, there are two main methods of improving the healthcare provided: seeking new treatment procedures and perfecting(optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring,but also implementation of general trends in the clinical practice. In depression, treatment-resistance to antidepressive pharmacotherapyrepresents one of the most important clinical challenges. Switch to monotherapy with new multimodal/multifunctionalantidepressants and augmentation with new atypical antipsychotics (aripiprazole and brexpiprazole) may be promising options.Further, current evidence supports...

Pharmacotherapy of Alzheimer disease and neuropsychiatric symptoms of dementia

PharmDr. Iva Prokopová, Ph.D.

Psychiatr. praxi 2018; 19(2): 58-63 | DOI: 10.36290/psy.2018.014  

Alzheimer disease is the most prevalent type of dementia. A precise diagnosis is required for effective management. Cholinesteraseinhibitors are used as first line therapy to provide modest symptomatic benefit in some patients, memantine appears tohave modest benefits in patients with moderate to severe disease. Neuropsychiatric symptoms are common in dementia andcontribute to nursing home admission and caregiver stress. Identifying the genesis of the abnormal behavior is critical, in orderthat nonpharmacologic therapies are preferred over medication. Symptomatic pharmacologic treatment includes antidepressants,antipsychotics, anxiolytics and other...

Huntington’s disease as a neuropsychiatric problem

doc. MUDr. Bc. Libor Ustohal, Ph.D., MUDr. Marie Obdržálková, Mgr. et Mgr. Monika Víchová

Psychiatr. praxi 2018; 19(2): 64-66 | DOI: 10.36290/psy.2018.039  

The article summarizes basic data about diagnostics and treatment of Huntington’s disease. It emphasizes the neuropsychiatricbasis of the disease with not only motor symptoms but also with various psychiatric symptoms and cognitive deficit. These factsare confirmed with one case study.

Psychiatric inpatient suicide in the Czech Republic

MUDr. Adam Žaludek, MBA

Psychiatr. praxi 2018; 19(2): 69-75 | DOI: 10.36290/psy.2018.015  

Inpatient suicide in psychiatric wards is a severe sentinel event. It influences the whole hospital. The article focuses on reccommendationof suicide prevention programme according to the current state in acute psychiatric wards in the Czech Republic,mentioning law circumstances. Data from the research were presented at the international conference XXXVth InternationalAcademy on Law and Mental Health which took place on July 9–14, 2017 in Prague.

Older patient treated with pregabalin for generalized anxiety disorder: a case study

doc. MUDr. Bc. Libor Ustohal, Ph.D.

Psychiatr. praxi 2018; 19(2): 76-79 | DOI: 10.36290/psy.2018.016  

Pregabalin is used with an increasing frequency for the treatment of generalized anxiety disorder. It is supposed to decreaseexcitatory neurotransmission by binding to the α2δ subunit of the P/Q-type of voltage-gated calcium channel. This case studypresents its efficacy and safety even in elderly. Moreover, pregabalin reduced the use of benzodiazepines as well as it influencedpain syndrome in our patient.

Forensic treatment – guidelines for health care providers

MUDr. Jiří Švarc, Ph.D., MUDr. Marek Páv, Ph.D., MUDr. Simona Papežová, MUDr. Martin Hollý, MBA

Psychiatr. praxi 2018; 19(2): 80-85  

The article introduces guidelines for health care providers (hereinafter referred to as "the Provider") in both outpatient and inpatientforensic treatment (FT). The guidelines are based on current legislation, an issue for which general psychiatrists lack theresources to keep updated on. The guidelines have been developed on the basis of the authors’ practical experience and thequestions most frequently asked by their colleagues, and have been implemented in the internal directives of the Bohnice PsychiatricHospital (process map). The article describes which legislation governs FT; on which offenders FT is imposed by the court;obligations of...

News in forensic treatment

MUDr. Jiří Švarc, Ph.D.

Psychiatr. praxi 2018; 19(2): 86-87  

The article deals with what is new in the legislation on forensic treatment: patients in inpatient forensic treatment can be reportedin category 5; end of prolongation of outpatient forensic treatment; change in the indication of therapeutic castration; changesin some notification obligations (in relation to the victim; in the case of escape from inpatient forensic treatment; in the case offailure to attend outpatient forensic treatment).